Publikasi Scopus 926 artikel (Per 14 Maret 2022)

Marwali E.M., Rayhan M., Roebiono P.S.
36608535400;57219904946;57192895321;
Nitroglycerin inhalation for acute treatment of pulmonary arterial hypertension in children with congenital heart disease
2021
Cardiology in the Young
31
9
1381
1385
Pediatric Cardiac Intensive Care Division, National Cardiovascular Center, Harapan Kita, Jakarta, Indonesia; Division of Pediatric Cardiology and Congenital Heart Disease, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center, Harapan Kita, Jakarta, Indonesia
Marwali, E.M., Pediatric Cardiac Intensive Care Division, National Cardiovascular Center, Harapan Kita, Jakarta, Indonesia; Rayhan, M., Pediatric Cardiac Intensive Care Division, National Cardiovascular Center, Harapan Kita, Jakarta, Indonesia; Roebiono, P.S., Division of Pediatric Cardiology and Congenital Heart Disease, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center, Harapan Kita, Jakarta, Indonesia
Abstract Objectives: Acute pulmonary hypertension and pulmonary hypertensive crisis may result in adverse clinical outcomes if unsuccessfully treated. Inhaled nitric oxide has long been considered as the standard pharmacotherapy for acute pulmonary hypertension, but lack of feasibility in some settings and evidences challenging its benefits lead to the use of alternative treatment, amongst which is nitroglycerin inhalation. The purpose of this review article is to discuss available data on the use of nitroglycerin inhalation for acute treatment of pulmonary hypertension in children with CHD and its potential benefit in post-operative setting. Data sources: Literatures included in this review were acquired by searching in PubMed online database. Keywords used were Pulmonary Hypertension, Congenital heart defects, Pediatrics, Inhaled nitroglycerin, and its synonyms. Study selection: Title and abstract were screened to select relevant literatures including the three paediatric clinical trials on nitroglycerin inhalation. Critical appraisal of the clinical trials was then done using the University of Oxford Centre of Evidence-Based Medicine Critical Appraisal Tools. Conclusions: Paediatric studies showed the benefit of nitroglycerin inhalation in uncorrected cases of CHD during catheterisation procedures. Until recently, there have been no studies conducted in paediatric post-operative CHD cases. Further study is required to provide evidence for inhaled nitroglycerin use in this setting including the appropriate dosing and potential side effects with repeated administration, ©
aerosolised nitroglycerin; congenital heart disease; corrective surgery; exogenous nitric oxide; Nitroglycerin inhalation; pulmonary arterial hypertension
glyceryl trinitrate; nitric oxide; phosphodiesterase V inhibitor; prostacyclin; prostacyclin derivative; prostaglandin E1; glyceryl trinitrate; clinical trial (topic); congenital heart disease; drug safety; emergency care; evidence based practice; heart catheterization; human; postoperative care; publication; pulmonary hypertension; Review; child; complication; congenital heart malformation; inhalational drug administration; pulmonary hypertension; Administration, Inhalation; Child; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Nitroglycerin; Pulmonary Arterial Hypertension
Cambridge University Press
10479511
34082850
Review
Q3
386
12454